Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Medicines Co. Stock

Price
 
€76.50
-
-0.650%
Target price
€130.00
03.01.20 / Tradegate WKN: 938858 / Symbol: MDCO / Name: Medicines / Stock / Pharmazeutika
Latest predictions
€180.00
21.12.19
buy
€80.00
25.09.19
buy
Your prediction

Medicines Co. Stock

The price for the Medicines Co. stock decreased slightly today. Compared to yesterday there is a change of €0.000 (-0.650%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Medicines Co. stock is not clear.
As a result the target price of €130.00 shows a very positive potential of 69.935% compared to the current price of €76.50 for Medicines Co..

Comments

Sell Medicines Co.

Published on 26.12.19
Prediction Sell
Target price
Change

Sell beendet

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Medicines Co. Stock

New thread

News

The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024


The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75%

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion


The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash

The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing


The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing


The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical

The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019


The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science